Decreased effectiveness of ischemic heart preconditioning in the state of chronic inflammation

Medical Hypotheses
M WojciechowskaD Szukiewicz

Abstract

There is growing evidence, that beneficial effects of ischemic heart preconditioning (IPC) may be lost or limited due to diabetes, hyperlipidemia, hypertension, atherosclerosis, heart failure and senility. It is plausible, that these conditions interfere with the biochemical pathways underlying the IPC response, but the detailed explanation is not clear. Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), monocyte chemotactic protein-1 (MCP-1), histamine and many other agents used in a single dose before prolonged ischemia mimic IPC. However prolonged exposure to preconditioning mimetics leads to tolerance (tachyphylaxis). In the state of such tolerance ischemic preconditioning is no longer protective. Studies suggest that diabetes, hyperlipidemia, hypertension, atherosclerosis, heart failure and older age are accompanied by increased plasma levels of pro-inflammatory cytokines, MCP-1 and other inflammatory mediators. Therefore, we raised the hypothesis, that the reported lack of benefits of IPC in the listed states may be due to tolerance to IPC developed during prolonged exposure of the myocardium to preconditioning mimetics.

References

Apr 30, 1992·Biochemical and Biophysical Research Communications·L J EddyG H Wong
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J M BrownJ E Repine
Dec 1, 1993·The Journal of Experimental Medicine·J PuginP S Tobias
Apr 1, 1995·Journal of Molecular and Cellular Cardiology·D M Yellon, G F Baxter
Nov 1, 1994·Diabetes·G S Hotamisligil, B M Spiegelman
Sep 1, 1994·Circulation Research·M E Speechly-DickD M Yellon
Mar 1, 1996·The Annals of Thoracic Surgery·P G BurnsS Levitsky
Dec 1, 1995·Journal of Molecular and Cellular Cardiology·Z SzilvassyM Koltai
Jan 1, 1997·Journal of Molecular and Cellular Cardiology·C P BainesJ M Downey
May 1, 1997·Circulation Research·I TrittoG Ambrosio
Mar 1, 1997·Journal of Molecular and Cellular Cardiology·E K IliodromitisD J Hearse
Apr 4, 1998·Journal of Molecular and Cellular Cardiology·P FerdinandyL Dux
Mar 31, 1998·Diabetes·M PendergrassL J Mandarino
Oct 14, 1998·Journal of Molecular and Cellular Cardiology·G HadourM de Lorgeril
Oct 30, 1998·Diabetologia·J C Pickup, M A Crook
Jun 8, 1999·The Journal of Experimental Medicine·N YamashitaM Hori
Apr 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·K M KurrelmeyerD L Mann
May 5, 2000·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·G LongobardiF Rengo
Jun 22, 2000·Journal of Molecular and Cellular Cardiology·R A FentonJ G Dobson
Aug 10, 2000·Journal of the American College of Cardiology·P AbeteF Rengo

❮ Previous
Next ❯

Citations

Oct 21, 2017·Aging Clinical and Experimental Research·Elpidio SantilloRaffaele Antonelli-Incalzi
Jul 7, 2017·Canadian Journal of Physiology and Pharmacology·Martina MurárikováTáňa Ravingerová

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Related Papers

Clinical Hemorheology and Microcirculation
Mary Clare LucaJohn D Parker
Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University
G LiE Lu
Chinese Journal of Traumatology = Zhonghua Chuang Shang Za Zhi
Y ZhangR Pan
© 2021 Meta ULC. All rights reserved